Esperion Therapeutics, Inc. (0IIM.L)
USD 2.27
(-8.85%)
USD 2.27
(-8.85%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 458.69 Million USD | 236.85% |
| 2022 | 136.17 Million USD | 165.42% |
| 2021 | 51.3 Million USD | 142.91% |
| 2020 | -119.55 Million USD | 27.35% |
| 2019 | -164.56 Million USD | -345.1% |
| 2018 | -36.97 Million USD | -10.62% |
| 2017 | -33.42 Million USD | 5.68% |
| 2016 | -35.43 Million USD | 51.49% |
| 2015 | -73.04 Million USD | 8.81% |
| 2014 | -80.1 Million USD | -41.68% |
| 2013 | -56.53 Million USD | -447.74% |
| 2012 | 16.25 Million USD | 205.25% |
| 2011 | 5.32 Million USD | 0.0% |
| 2002 | -31.7 Million USD | 50.41% |
| 2001 | -63.94 Million USD | 3.85% |
| 2000 | -66.5 Million USD | -2028.36% |
| 1999 | -3.12 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 367.33 Million USD | 13.98% |
| 2024 Q1 | 322.26 Million USD | -29.74% |
| 2023 Q3 | 149.29 Million USD | 19.77% |
| 2023 FY | 458.69 Million USD | 236.85% |
| 2023 Q4 | 458.69 Million USD | 207.24% |
| 2023 Q2 | 124.65 Million USD | 7.01% |
| 2023 Q1 | 116.49 Million USD | -14.45% |
| 2022 Q3 | 100.82 Million USD | -26.53% |
| 2022 FY | 136.17 Million USD | 165.42% |
| 2022 Q4 | 136.17 Million USD | 35.05% |
| 2022 Q2 | 137.23 Million USD | 24.99% |
| 2022 Q1 | 109.79 Million USD | 114.01% |
| 2021 Q4 | 51.3 Million USD | -70.27% |
| 2021 FY | 51.3 Million USD | 142.91% |
| 2021 Q3 | 172.55 Million USD | 201.78% |
| 2021 Q2 | 57.17 Million USD | -2.45% |
| 2021 Q1 | 58.61 Million USD | 149.03% |
| 2020 Q1 | -143.75 Million USD | 12.65% |
| 2020 Q3 | -209.01 Million USD | 28.49% |
| 2020 FY | -119.55 Million USD | 27.35% |
| 2020 Q2 | -292.29 Million USD | -103.33% |
| 2020 Q4 | -119.55 Million USD | 42.8% |
| 2019 Q3 | -210.89 Million USD | 22.86% |
| 2019 Q4 | -164.56 Million USD | 21.97% |
| 2019 FY | -164.56 Million USD | -345.1% |
| 2019 Q1 | -173.86 Million USD | -370.24% |
| 2019 Q2 | -273.38 Million USD | -57.24% |
| 2018 Q3 | -26.75 Million USD | -10.43% |
| 2018 Q1 | -30.22 Million USD | 9.58% |
| 2018 FY | -36.97 Million USD | -10.62% |
| 2018 Q4 | -36.97 Million USD | -38.19% |
| 2018 Q2 | -24.22 Million USD | 19.83% |
| 2017 Q4 | -33.42 Million USD | -71.01% |
| 2017 Q2 | -18.46 Million USD | -5.27% |
| 2017 Q1 | -17.54 Million USD | 50.49% |
| 2017 FY | -33.42 Million USD | 5.68% |
| 2017 Q3 | -19.54 Million USD | -5.83% |
| 2016 Q1 | -33.29 Million USD | 54.42% |
| 2016 FY | -35.43 Million USD | 51.49% |
| 2016 Q4 | -35.43 Million USD | 19.48% |
| 2016 Q2 | -45.24 Million USD | -35.88% |
| 2016 Q3 | -44 Million USD | 2.73% |
| 2015 Q4 | -73.04 Million USD | 4.09% |
| 2015 FY | -73.04 Million USD | 8.81% |
| 2015 Q1 | -203.75 Million USD | -154.37% |
| 2015 Q2 | -124.88 Million USD | 38.71% |
| 2015 Q3 | -76.16 Million USD | 39.02% |
| 2014 Q1 | -48.63 Million USD | 13.97% |
| 2014 Q3 | -35.3 Million USD | 17.94% |
| 2014 Q4 | -80.1 Million USD | -126.9% |
| 2014 FY | -80.1 Million USD | -41.68% |
| 2014 Q2 | -43.02 Million USD | 11.55% |
| 2013 Q1 | -20.88 Million USD | -228.46% |
| 2013 Q2 | -16.62 Million USD | 20.39% |
| 2013 Q3 | -71.89 Million USD | -332.41% |
| 2013 Q4 | -56.53 Million USD | 21.36% |
| 2013 FY | -56.53 Million USD | -447.74% |
| 2012 Q4 | 16.25 Million USD | 0.0% |
| 2012 FY | 16.25 Million USD | 205.25% |
| 2011 FY | 5.32 Million USD | 0.0% |
| 2003 Q1 | -22.8 Million USD | 28.08% |
| 2003 Q3 | -55.55 Million USD | -190.03% |
| 2003 Q2 | -19.15 Million USD | 15.99% |
| 2002 FY | -31.7 Million USD | 50.41% |
| 2002 Q2 | -37.28 Million USD | 33.34% |
| 2002 Q3 | -33.19 Million USD | 10.99% |
| 2002 Q1 | -55.93 Million USD | 12.52% |
| 2002 Q4 | -31.7 Million USD | 4.47% |
| 2001 Q2 | -47.48 Million USD | 21.72% |
| 2001 Q4 | -63.94 Million USD | 9.49% |
| 2001 FY | -63.94 Million USD | 3.85% |
| 2001 Q1 | -60.65 Million USD | 8.79% |
| 2001 Q3 | -70.64 Million USD | -48.79% |
| 2000 Q1 | -25.07 Million USD | 0.0% |
| 2000 FY | -66.5 Million USD | -2028.36% |
| 2000 Q2 | -20.21 Million USD | 19.4% |
| 2000 Q3 | -72.66 Million USD | -259.44% |
| 2000 Q4 | -66.5 Million USD | 8.47% |
| 1999 FY | -3.12 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 626.538% |
| Dynavax Technologies Corporation | 106.63 Million USD | -330.158% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 1468.148% |
| Perrigo Company plc | 3.32 Billion USD | 86.192% |
| Illumina, Inc. | 1.21 Billion USD | 62.216% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 98.291% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 502.763% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 94.43% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 96.432% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -216.178% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 1792.616% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -6282.343% |
| Waters Corporation | 1.96 Billion USD | 76.602% |
| Biogen Inc. | 6.28 Billion USD | 92.706% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 6560.549% |
| Evolus, Inc. | 63.7 Million USD | -620.002% |
| Adicet Bio, Inc. | -142 Million USD | 423.009% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 5187.611% |
| bluebird bio, Inc. | 108.57 Million USD | -322.488% |
| FibroGen, Inc. | 56.76 Million USD | -708.038% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 59.939% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -6482.864% |
| Homology Medicines, Inc. | 18.43 Million USD | -2387.926% |
| Geron Corporation | 14.76 Million USD | -3007.506% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 71.066% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -131.59% |
| Myriad Genetics, Inc. | 88.1 Million USD | -420.657% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 945.435% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 511.751% |
| Zoetis Inc. | 4.76 Billion USD | 90.368% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 4654.652% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 78.136% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -21.109% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 104.796% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 3247.811% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 56.491% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -1338.604% |
| Verastem, Inc. | -37.27 Million USD | 1330.482% |
| Nektar Therapeutics | 210.24 Million USD | -118.179% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 329.555% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 1346.329% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 52.632% |
| OPKO Health, Inc. | 230.68 Million USD | -98.844% |
| Exelixis, Inc. | -73.05 Million USD | 727.925% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -158.713% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 438.773% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 403.726% |
| uniQure N.V. | -102.95 Million USD | 545.551% |
| Imunon, Inc. | -4.69 Million USD | 9861.063% |
| Blueprint Medicines Corporation | 702.83 Million USD | 34.736% |
| Insmed Incorporated | 721.62 Million USD | 36.435% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 66.782% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 1569.388% |
| TG Therapeutics, Inc. | 17.86 Million USD | -2468.016% |
| Incyte Corporation | -3.17 Billion USD | 114.447% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 40.102% |